LIBTAYO is indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative …
LIBTAYO is indicated for the treatment of patients with metastatic or locally advanced CSCC who are not candidates for curative surgery or curative radiation. Review Important Safety …
LIBTAYO in combination with platinum-based chemotherapy is indicated for the first-line treatment of adult patients with non–small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1
LIBTAYO is indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative …
LIBTAYO is indicated as a 1L treatment in certain advanced NSCLC as a monotherapy with PD-L1 expression ≥ 50% and no EGFR, ALK, ROS1, and combination therapy with platinum …
View Study 1423 and Study 1540 trial designs used to evaluate the efficacy and safety of LIBTAYO in metastatic or locally advanced CSCC in patients who were not candidates for …
What is the LIBTAYO Surround Provider Portal? • The Provider Portal is an online resource that HCP offices can utilize when requesting LIBTAYO Surround services. It offers a way to enroll, …
For any questions or concerns, or to report side effects with a Regeneron product for patients enrolled in LIBTAYO Surround, please contact LIBTAYO Surround at 1.877.LIBTAYO …
Cemiplimab-rwlc (LIBTAYO ®) is recommended by national guidelines for advanced BCC 9. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for Basal Cell Skin …